Previous clinical trial investigations have established that daratumumab plus bortezomib, melphalan and prednisone, also known as dara+VMP, is significantly more effective than VMP alone in terms of response and progression-free survival in multiple myeloma (MM). Speaking from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, provides us with an update on the feasibility and tolerability of daratumumab, and explains how the drug can now be conveniently administered as a subcutaneous infusion, as well as to elderly patients.
